Attach to Form 990 or Form 990-EZ.
Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.
| (i)Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Total | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any unusual grants.) .... | 33,572,100 | 39,413,484 | 41,532,901 | 47,770,745 | 48,376,154 | 210,665,384 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 33,572,100 | 39,413,484 | 41,532,901 | 47,770,745 | 48,376,154 | 210,665,384 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 0 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 210,665,384 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 33,572,100 | 39,413,484 | 41,532,901 | 47,770,745 | 48,376,154 | 210,665,384 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 15,165,483 | 16,370,797 | 14,057,593 | 3,644,064 | 4,866,437 | 54,104,374 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 0 | |||||
| 11 | Total support. Add lines 7 through 10. | 264,769,758 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2011 | (b) 2012 | (c) 2013 | (d) 2014 | (e) 2015 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2015 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2015 |
(iii) Distributable Amount for 2015 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2015 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2015 (reasonable cause required--see instructions) |
||||
| 3 Excess distributions carryover, if any, to 2015: | ||||
| a | ||||
| b | ||||
| c | ||||
| d From 2013....... | ||||
| e From 2014....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2015 distributable amount | ||||
|
i
Carryover from 2010 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2015 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2015 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2015, if any. Subtract lines 3g and 4a from line 2 (if amount greater than zero, see instructions) |
||||
|
6
Remaining underdistributions for 2015. Subtract lines 3h and 4b from line 1 (if amount greater than zero, see instructions) |
||||
|
7 Excess distributions carryover to 2016. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a | ||||
| b | ||||
| c Excess from 2013....... | ||||
| d From 2014....... | ||||
| e From 2015....... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Information about Schedule O (Form 990 or 990-EZ) and its instructions is at| Return Reference | Explanation |
|---|---|
| FORM 990 PART I, LINE 1 & PART III, LINE 1 | THE MASSACHUSETTS EYE AND EAR INFIRMARY ("THE INFIRMARY") IS A NOT-FOR-PROFIT TEACHING HOSPITAL CONDUCTING PATIENT CARE AND RESEARCH. THE INFIRMARY IS A TEACHING HOSPITAL OF HARVARD MEDICAL SCHOOL AND AN INTERNATIONAL CENTER FOR RESEARCH. IT HAS THE MOST COMPETITIVE PROGRAM IN THE COUNTRY FOR EYE, EAR, NOSE, AND THROAT RESIDENCY TRAINING AND THE WORLD'S LARGEST OPHTHALMIC FELLOWSHIP PROGRAM. IT IS PART OF A SYSTEM OF RELATED ENTITIES THAT PROVIDE SPECIALIZED MEDICAL CARE COLLECTIVELY KNOWN AS "MASSACHUSETTS EYE AND EAR INFIRMARY" ("MEEI"). FORM 990, PART III, LINE 4A: Massachusetts Eye and Ear is a specialty hospital dedicated to excellence in the care of disorders that affect the eye, ear, nose, throat and adjacent regions of the head and neck. 2016 was an exceptional year: U.S. News & World Report ranked the Mass. Eye and Ear Department of Otolaryngology #1 in the nation for the second consecutive year and the Department of Opthalmology #4 in the nation; growth throughout eighteen clinical locations; advancements in research; academic excellence; commitment to community; and the implementation of two major technology transitions, PeopleSoft, which is the system Mass. Eye and Ear uses for all enterprise resource planning (payroll, general ledger, HR) and Epic, our new, unified patient care system. They are both considered the premier products in their field and have an impact on virtually every person in the Mass. Eye and Ear community. |
| RESEARCH | Ophthalmology Significant Awards/Honors Ula Jurkunas, MD: American Academy of Ophthalmology Achievement Award Richard Masland, PhD: Distinguished Research Achievement Awardee, Harvard Ophthalmology Eric Pierce, MD, PhD: 2016 Alcon Research Institute Award David Sullivan, PhD: ARVO Gold Fellow Demetrios Vavvas, MD, PhD: Pfizer Ophthalmics Carl Camras Translational Research Award Janey Wiggs, MD, PhD: Inducted into Academia Ophthalmologica Internationalis AMD Center of Excellence Patients with high-risk macular degeneration show improvement with high-dose statin treatment Joan W. Miller, MD, and Demetrios Vavvas, MD, PhD, led colleagues from Mass. Eye and Ear/Harvard Medical School and a University in a Phase I/II clinical trial that found that high dose statin treatment carries the potential for clearing lipid debris that is associated with vision impairment in patients with high-risk macular degeneration. Their findings not only furthered the connection among lipids, age-related macular degeneration (AMD) and atherosclerosis, but also present a potential therapy for some patients with dry AMD, for which treatments are currently lacking. As a next step, investigators are planning a larger, prospective multicenter trial to further investigate the efficacy of the treatment in a larger sample of patients with dry AMD. Researchers shed light on the anti-adhesive molecule in vascular endothelium suggesting new direction for anti-inflammatory therapy Mass. Eye and Ear researchers led by Patricia DAmore, PhD, MBA and Pablo Argeso, PhD have gained new insight into how a non-inflammatory state is maintained in the body. Their findings suggest that promoting the expression of endomucin may prevent the recruitment of white blood cells that is the hallmark of inflammation. The research shows that in healthy, non-inflamed tissue, endomucin plays a critical role in preventing neutrophils from sticking to the endothelium. During inflammatory conditions, however, the endomucin on the endothelial cell surface is dramatically reduced and the levels of pro-adhesives molecules on the endothelium increase, resulting in neutrophil accumulation. The researchers showed both adherence and infiltration of inflammatory cells could be blocked by experimentally expressing excess endomucin in the vascular endothelium. This new knowledge may be used to develop treatments for inflammation by promoting the expression of endomucin to prevent the movement of inflammatory cells from the capillaries into inflamed tissues. Cornea Center of Excellence Translational Research on Lubricin Demonstrates Significant Improvement of Multiple Signs and Symptoms of Dry Eye Disease David A. Sullivan, PhD, in collaboration with colleagues from several institutions worldwide, evaluated the use of recombinant human lubricin as a treatment for patients with dry eye disease. A clinical trial based on this research, the results of which were published ahead of print in September by The Ocular Surface, showed significant improvement in signs and symptoms of dry eye disease compared to sodium hyaluronate without adverse events during the investigation. Researchers find stem cells in normal and Fuchs corneal endothelium Ula Jurkunas, MD, was the principal investigator of a study that has, for the first time, identified stem cells not only in normal corneal endothelium but also in corneal endothelium of patients with Fuchs' endothelial corneal dystrophy (FECD). Corneal transplantation is the only currently accepted therapy for FECD. This finding holds promise for new therapies to be developed that possibly promote the division of patients' own stem cells and allow the cornea to clear without a need for corneal transplantation in FECD patients. Restoration of Corneal Transparency by Mesenchymal Stem Cells A study led by Sunil Chauhan, PhD, has identified hepatocyte growth factor (HGF), secreted by mesenchymal stem cells, as the key factor responsible for restoring corneal transparency and promoting wound healing in preclinical models of corneal injury. The findings suggest that HGF-based treatments may be effective in restoring vision in patients with severely scarred corneas. Researchers identify factors responsible for chronic nature of autoimmune disease Reza Dana, MD, MSc, MPH, and colleagues uncovered two factors responsible for the chronic, lifelong nature of autoimmune disorders, which tend to flare up intermittently in affected patients. These two factors are cell-signaling proteins called cytokines - specifically Interleukin-7 and -15 (IL-7 and IL-15)-that are secreted by cells of the immune system and help modulate memory Th17 cells, a subset of T cells which are known to contribute to autoimmune disorders. Until now, it was unclear how Th17 cells maintained memory; the study results show that IL-7 and IL-15 signal the Th17 cells to chronically reside in the body. These findings may lead to the development of new therapies to address a variety of chronic autoimmune disorders. Diabetic Eye Disease Center of Excellence Growth factor shown to protect the retina in early stage diabetes Mara Lorenzi, MD, and colleagues have shown that a slight increase in transforming growth factor beta (TGF-), which is present in preclinical animal models with diabetic eye disease, protects retinal blood vessels from damage that commonly occurs in the early stages of the disease (known as diabetic retinopathy). Their findings may lead to targeted therapeutics that delay or prevent the development of the disease in patients. Glaucoma Center of Excellence Three new genes identified that contribute to primary open-angle glaucoma In the largest genome-wide study of its kind, Janey Wiggs, MD, PhD and collaborators from HMS Ophthalmology and Case Western Reserve University School of Medicine, identified three genes that contribute to the primary open-angle glaucoma (POAG), which is the most common type of glaucoma. Researchers conducted a meta-analysis of genome-wide association study (GWAS) results from 3,853 people with POAG and compared them to a control group of 33,480 people of European descent using human genomes collected through the NEIGHBORHOOD consortium, a National Eye Institute collaborative. After replicating the analysis using data from an Australian study, and comparing the analysis to three more data sets (Australia, Europe, China), three susceptibility loci were identified: TXNRD2, ATXN2, and FOXC1. The findings provide key insight that ultimately may be used to develop gene-based testing and treatment strategies for glaucoma. Infectious Disease Institute Mass. Eye and Ear Team Discovers and Successfully Treats New Variant of Antibiotic-resistant Bacterium Michael Gilmore, PhD, and colleagues discovered and successfully treated a new mutation in a highly antibiotic-resistant strain of E. coli that resists clearance by the bodys own immune system by inhibiting white blood cells that ordinarily kill and remove bacteria. They found that, in addition to its elevated resistance to antibiotics, this bacterium produced a layer of slime on its surface that prevented white blood cells from trapping and killing the microbe, something researchers have not seen before in this type of E. coli. Mobility Enhancement and Vision Rehabilitation Center of Excellence Research aims to reduce pedestrian collisions in crowded and chaotic open space environments Vision scientists may have discovered how to reduce pedestrian collisions in crowded and chaotic open space environments like bus terminals, shopping malls and city plazas involving individuals with partial blindness. Eli Peli, OD, and colleagues have determined from which direction collisions with partially blind pedestrians are most likely to originate by creating a mathematical model to determine risk, and comparing that risk to the limited vision of 42 patients with retinitis pigmentosa. This understanding will guide the development of new glasses that expand the sight of a person with limited peripheral vision. Ocular Genomics Institute Gene therapy restores hearing in deaf mice...down to a whisper |
| In the summer of 2015, a team at Boston Childrens Hospital and | Harvard Medical School reported restoring rudimentary hearing in genetically deaf mice using gene therapy. Now the Boston Childrens research team reports restoring a much higher level of hearing - down to 25 decibels, the equivalent of a whisper - using an improved gene therapy vector developed at Massachusetts Eye and Ear. While previous vectors have only been able to penetrate the cochleas inner hair cells, the first Nature Biotechnology study showed that a new synthetic vector, Anc80, safely transferred genes to the hard-to-reach outer hair cells when introduced into the cochlea. This studys three Harvard Medical School senior investigators were Jeffrey R. Holt, PhD, of Boston Childrens Hospital; Konstantina Stankovic, MD, PhD, of Mass. Eye and Ear and Luk H. Vandenberghe, PhD, who led Anc80s development in 2015 at Mass. Eye and Ears Grousbeck Gene Therapy Center. Other Research New Insights into Thyroid Eye Disease Treatments Nahyoung Grace Lee, MD, Leo Kim, MD, PhD, and colleagues identified new mechanisms of proptosis, or bulging of the eyes, in patients with acute thyroid eye disease, which opens a path to exploring non-surgical treatments for thyroid eye disease. Currently, oral or IV steroids and major surgery (to break the bones behind the eyes) are the only viable option to prevent severe and permanent vision loss in patients with thyroid eye disease, but these results suggest that it might be possible to treat the inflammation and swelling by stopping the blood vessels from forming and leaking fluid, or, alternatively, by finding a way to promote lymphatic vessel formation and enhance drainage of fluid. Otolaryngology FY16 New Faculty - Yoojin Chung, PhD (promoted from training status) - Nima Maftoon, PhD (promoted from training status) - Sunil Puria, PhD Faculty Accomplishments - Dr. David Jung won the 2016 American Neurotology Society AAO-HNSF Herbert Silverstein Otology and Neurotology Research Award. - Dr. Leila Mankarious became the Harvard Medical School Director of Hearing Registries at Mass. Eye and Ear. - Dr. Xiying Guan received the Emerging Research Grant from the Hearing Health Foundation for his research proposal on hyperacusis. - Dr. M. Charles Liberman was appointed Committee Chair to write the 2017 2021 Strategic Plan for the National Institute for Deafness and Other Communicative Disorders. - A story on "hidden hearing loss," featuring research from Drs. Stphane Maison and Charlie Liberman, appeared in the print edition of the Wall Street Journal, the highest circulation newspaper in the U.S., on September 27. Anesthesia Research successes Grants: Andres Macias, MD - "Identifying and Correcting Preventable Errors by Improving Communication Between Providers in The Post-Anesthesia Care Unit through Implementation of an Automated Electronic Checklist" ending October 2016 Poster presentations: Comins J, Hartnick C, Sahani N. What should we know about Hypoglossal Nerve Stimulator in adolescent patients with Obstructive sleep apnea? Poster presentation at Harvard Pediatric Clinical Update., Boston Childrens Hospital, Boston, May 2016 Publications: Macias AA, Eappen S, Malikin I, Goldfarb J, Kujawa S, Konowitz PM, Kamani D, Randolph GW. Successful intraoperative electrophysiologic monitoring of the recurrent laryngeal nerve, a multidisciplinary approach: The Massachusetts Eye and Ear Infirmary monitoring collaborative protocol with experience in over 3000 cases. Head Neck. 2016 Apr 9. Lectures: Joseph Bayes, MD- invited speaker on Perioperative Management of Adults with Obstructive Sleep Apnea, at the MEE/Harvard Course on Obstructive Sleep Apnea at MEE. September 2016. Radiology Highlights The radiologists wrote or participated in 40 papers including: - Fuller JC, Sinha S, Caruso PA, Hersch CJ, Butler WE, Krishnamoorty KS, Hartnick CJ. Chiari malformations: An important cause of pediatric aspiration. Int J Pediatr Otorhinolaryngol. 2016 Sep;88:124-8. - Eichler FS, Li J, Guo Y, Caruso PA, et al. CSF1R mosaicism in a family with hereditary diffuse leukoencephalopathy with spheroids. Brain. 2016 J eun;139(Pt 6):1666-72. - Cunnane MB, Curtin HD. Imaging of orbital disorders. Handb Clin Neurol. 2016;135:659-72. - Radhakrishnan R, Cornelius R, Cunnane MB, Golnik K, Morales H. MR imaging findings of endophthalmitis. Neuroradiol J. 2016 Apr;29(2):122-9. - Kandathil CK, Cunnane MB, McKenna MJ, Curtin HD, Stankovic KM. Correlation between aspirin intake and reduced growth of human vestibular schwannoma: Volumetric analysis. Otol Neurotol. 2016 Oct;37(9):1428-34. - Curtin HD. Imaging of conductive hearing loss with a normal tympanic membrane. Am J Roentgenol. 2016 Jan;206(1):49-56. - Juliano AF, Ting EY, Mingkwansook V, Hamberg LM, Curtin HD. Vestibular aqueduct measurements in the 45? oblique (Pschl) plane. Am J Neuroradiol. 2016 Jul;37(7):1331-7. - Ochoa-Escudero M, Juliano AF. Unilateral hypoplasia with contralateral hypertrophy of anterior belly of digastric muscle: A case report. Surg Radiol Anat. 2016 Oct;38(8):973-4. - Kelly HR, Curtin HD. Imaging of skull base lesions. Handb Clin Neurol. 2016;135:637-57 (PubMed in process). - Lam S, Gupta R, Kelly HR, Curtin HD, Forghani R. Multiparametric evaluation of head and neck squamous cell carcinoma using a single-source dual-energy CT with fast kVp switching: State of the art. Cancers (Basel). 2016 Nov 6;7(4):2201-16. - Leung KJ, Quesnel AM, Juliano AF, Curtin HD. Correlation of CT, MR and histopathology in incomplete partition-II cochlear anomaly. Otol Neurotol. 2016 Jun;37(5):434-7. - Qu J, Qin L, Cheng S, Leung K, et al: Residual low ADC and high FA at the resection margin correlate with poor chemoradiation response and overall survival in high-grade glioma patients. Eur J Radiol. 2016 Mar;85(3):657-64. - Garzorz N, Diercks GR, Lin HW, Faquin WC, Romo LV, Hartnick CJ. A case of pediatric parapharyngeal space ganglioneuroma. Ear Nose Throat J. 2016 Apr-May;95(4-5):E16-20. Other achievements Several faculty members were invited speakers and presented scientific papers at the following societies: - American Society of Head and Neck Radiology (ASHNR) - American Society of Neuroradiology (ASNR) - Eastern Neuroradiological Society (ESNR) - North American Skull Base Society (NASBS) - Radiological Society of North America (RSNA) Research successes -Dr. Amy Juliano has a new NIH grant as co-investigator: Extraorally Delivered Low Level Light Therapy for Prevention of Oropharyngeal Mucositis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: Sponsor name: National Institutes of Health; Principal Investigator: Nathaniel Treister, DMD, DMSc. This is a joint project with BWH, DFCI and the University of Massachusetts, Lowell. Accreditation -The department is currently accredited by the American College of Radiology (ACR) for CT and MRI and remains in good standing. |
| FORM 990, PART III, LINE 4B | Education Harvard Medical School Training Programs A Harvard Medical School teaching hospital, Mass. Eye and Ear trains future medical leaders in ophthalmology and otolaryngology, through residency as well as clinical and research fellowships. Academic Programs Ophthalmology -24 Residents -32 Clinical Fellows -125 Research Fellows -1 Optometry Resident Otolaryngology -18 Residents -11 Clinical Fellows -55 Research Fellows -2 Research Residents - Joan W. Miller, MD elected to the National Academy of Medicine - Stacey T. Gray, MD chair elect for American Academy of Otolaryngology-Head and Neck Surgery Rhinology and Allergy Education Committee Endowed Chairs - Demetrios G. Vavvas, MD, PhD first incumbent of the Monte J. Wallace Ophthalmology Chair in Retina at Mass. Eye and Ear - Gregory Randolph, MD first incumbent of the Claire and John Bertucci Professorship in Otolaryngology at Harvard Medical School Leaders in community service - More than 500 vision and hearing screenings for children - Innovative internship programs for high school students and visually impaired adults - Free public seminars/health fairs to share research and clinical advances in specialties - Community organization sponsorships and volunteerism Opthalmology Significant Awards/Honors Joseph Arboleda-Velasquez, MD, PhD: Young Mentor Award, HMS Patricia D'Amore, PhD, MBA: William Silen Lifetime Achievement in Mentoring Award, HMS Reza Dana, MD, MSc, MPH: Elected to Academia Ophthalmologica Internationalis Reza Dana, MD, MSc, MPH: 2016 Endre A. Balazs Prize, International Society for Eye Research Reza Dana, MD, MSc, MPH: Kersley Medal, British Ocular Surface Society Claes Dohlman, MD, PhD, and Joan W. Miller, MD: Appointed honorary Heed Fellows Facility/Programmatic - Launch of the Altschuler Surgical Training Lab - New, one-year medical retina fellowship directed by Deeba Husain, MD (will be offered in July, 2017) Note: This fellowship is in addition to the existing Medical Retina Fellowship at MEE - New, one-year anterior segment fellowship directed by Kathryn Hatch, MD (will be offered in July, 2017) - The ACGME-accredited Oculoplastics Surgery Fellowship received accreditation from the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS), directed by Michael Yoon, MD Otolaryngology Faculty Accomplishments - Dr. Alicia Quesnel was named the recipient of the 2016 Eleanor and Miles Shore Fellowship Program Award for Scholars in Medicine. - Dr. Aaron Remenschneider received the MGH Research Fellow Poster Award for Excellence - Dr. Elliott Kozin was selected as one of eleven 2016 Star Reviewers for the journal Otolaryngology - Head and Neck Surgery - Dr. Michael McKenna gave the AAO-HNSF/International Hearing Foundation/Michael M. Paparella, MD Endowed Lecture for Distinguished Contributions in Clinical Otology. Facility/Programmatic Headlines - The 14th Triennial International Otopathology Meeting was held at Mass. Eye and Ear. Radiology Highlights - For FY16, the Department of Radiology had a total of 81 residents and fellows join Dr. Curtin and faculty for daily read out sessions and head and neck imaging training (39 from MGH, 28 from BWH, and 14 from BIDMC). Faculty awards and prizes - Dr. Paul Caruso won the Derek Harwood-Nash award for the best oral presentation for the American Society of Pediatric Neuroradiology at the American Society of Neuroradiology meeting in May 2016 in Washington, DC. The presentation was on "Effect of Early MRI on the Management of Pediatric Traumatic Brain Injury". Pediatric Traumatic Brain Injury". FORM 990, PART III, LINE 4C Clinical Care - Completed renovation of 12 surgical suites (ORs) on main campus - Opened new ophthalmology surgical training lab - Opened new ear, nose, throat, and hearing care service in Wellesley. - Launched Center for Thyroid Eye Disease and Orbital Surgery (Joint EYE/ENT) - Joan Miller, MD: elected into the National Academy of Medicine - Dr. Gregory Randolph was elected President of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). He served as President Elect from October 2015 to September 2016 and starting in October 2016, he began serving as President. - Dr. Steven Rauch received the 2015 Champion of Vestibular Medicine award from the Vestibular Disorders Association. - Dr. Michael Cohen became the Director of the Multidisciplinary Pediatric Hearing Loss Clinic at Mass. Eye and Ear. - Sunil Eappen, MD promoted to - Associate Professor of Anesthesia - Anesthesia MOR office renovation - Office 712D office renovation - 23 MindRay Anesthesia machines - 5 Glidescope video laryngoscopes - Radiology will be implementing a new voice recognition program with Nuance Powerscribe (which is currently used at both MGH & BWH). - Radiology implemented Radimetrics, a new radiation dose management system from Bayer. New Hires: Radiology - Dr. Katherine Leung, full time staff radiologist Anesthesiology - Stephen Campo, MD- Staff Anesthesiologist - Ivanka Choumanova, MD- Staff Anesthesiologist - Susan Darrah, MD- Staff Anesthesiologist - Iuliu Fat, MD- Staff Anesthesiologist - Lisa Hammond, MD- Staff Anesthesiologist - Yuka Kiyota, MD- Staff Anesthesiologist - Suzanna Panitsas, MD- Staff Anesthesiologist - Yana Levin, MD- Staff Anesthesiologist - Matthew Mulholland, CRNA - Laura Weiner, CRNA Ophthalmology - Ryan Vasan, MD - Jan Kylstra, MD - Seanna Grob, MD - Veena Rao, MD - Richard Watson, MD - Milica Margeta, MD, PhD - Hajirah Saeed, MD - Xiaohong Zhou, OD - Silas Wang, MD Otolaryngology - Blake C. Alkire, MD, MPH - Caroline A. Banks, MD - Samir M. Bhatt, MD (named ENT Medical Director of Newton-Wellesley) - Gillian R. Diercks, MD - Nathan Jowett, MD, FRCSC - Aaron K. Remenschneider, MD, MPH - Jeremy D. Richmon, MD - Jeremy D. Richmon, MD |
| FORM 990, PART VI, LINE 1A | THE INFIRMARY'S BYLAWS STATE THE FOLLOWING: THERE SHALL BE AN EXECUTIVE COMMITTEE CONSISTING OF THOSE INDIVIDUALS WHO ARE SERVING AS MEMBERS OF THE EXECUTIVE COMMITTEE OF THE MEMBER. THE EXECUTIVE COMMITTEE SHALL HAVE THE POWER TO TRANSACT ALL EMERGENCY BUSINESS OF THE CORPORATION DURING THE PERIOD BETWEEN THE MEETINGS OF THE BOARD OF DIRECTORS. THE EXECUTIVE COMMITTEE SHALL ALSO TRANSACT SUCH BUSINESS, PERFORM SUCH DUTIES, AND EXERCISE SUCH POWERS AS MAY BE DIRECTED OR DELEGATED BY THE BOARD OF DIRECTORS FROM TIME TO TIME. THE EXECUTIVE COMMITTEE SHALL KEEP A RECORD OF ITS PROCEEDINGS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE SHALL BE REPORTED TO THE BOARD OF DIRECTORS AT ITS NEXT REGULAR MEETING. FORM 990, PART VI, LINE 7A: THE GOVERNOR OF THE COMMONWEALTH HAS THE AUTHORITY TO APPOINT TWO DIRECTORS. THE BYLAWS OF THE INFIRMARY STATE THAT THE REMAINING DIRECTORS ARE THOSE INDIVIDUALS SERVING AS DIRECTORS OF ITS SOLE MEMBER, THE FOUNDATION OF THE MASSACHUSETTS EYE AND EAR INFIRMARY, INC. ("THE FOUNDATION"). |
| FORM 990, PART VI, LINE 7B | THE FOUNDATION IS THE SOLE MEMBER OF THE INFIRMARY AND RETAINS THE AUTHORITY TO MAKE DECISIONS REGARDING THE INFIRMARY. |
| FORM 990, PART VI, LINE 11B | THE INFIRMARY'S FORM 990 IS PREPARED BY PRICEWATERHOUSECOOPERS, LLP USING INFORMATION PREPARED BY MANAGEMENT. AFTER THE FORM 990 IS COMPLETED, IT IS REVIEWED BY THE MANAGER OF INVESTMENTS AND FOUNDATION ACCOUNTING. THE FORM 990 IS THEN PRESENTED TO THE FINANCE COMMITTEE FOR REVIEW AND APPROVAL AS AUTHORIZED BY THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ARE ALSO GIVEN THE FORM 990 FOR REVIEW WITH TIME TO SUBMIT COMMENTS AND QUESTIONS BEFORE FINAL FILING. |
| FORM 990, PART VI, LINE 12C | MEMBERS OF THE STAFF ARE REQUIRED TO DISCLOSE CONFLICTS OF INTEREST TO THEIR CHIEF OF SERVICE OR DEPARTMENT AND DIRECTOR OF LABORATORY/UNIT. MEMBERS OF THE BOARD OF DIRECTORS ARE REQUIRED TO DISCLOSE ANNUALLLY, IN WRITING, ANY INTERESTS THAT COULD GIVE RISE TO CONFLICTS. THE OFFICE OF THE INTERNAL LEGAL COUNSEL OBTAINS AND REVIEWS THE ANNUAL CONFLICTS OF INTEREST STATEMENTS SUBMITTED BY MEMBERS OF THE BOARD OF DIRECTORS, AND REPORTS ON THE SAME TO THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD. WITH RESPECT TO INTERESTS DISCLOSED BY BOARD MEMBERS THAT COULD GIVE RISE TO CONFLICTS OF INTEREST, THE INTERNAL LEGAL COUNSEL REVIEWS ALL TRANSACTIONS BETWEEN SUCH INTERESTS AND AFFILIATES OF THE INFIRMARY, TO DETERMINE WHETHER THESE TRANSACTIONS WERE CONDUCTED AT ARM'S LENGTH. |
| FORM 990, PART VI, LINE 15 | THE CHAIRMAN OF THE COMPENSATION COMMITTEE OF THE BOARD OF THE INFIRMARY PRESENTS A RECOMMENDATION TO THE COMPENSATION COMMITTEE WHO HAVE FINAL APPROVAL OF THE CEO'S BASE SALARY AND BONUS AMOUNT. THE CEO RECOMMENDS THE SALARIES OF THE CHIEFS AND VICE PRESIDENTS TO THE COMPENSATION COMMITTEE OF THE BOARD WHO HAS FINAL AUTHORIZATION TO APPROVE IT. COMPENSATION OF THOSE AT THE DIRECTOR LEVEL, INCLUDING THE DIRECTOR OF PROFESSIONAL REVENUE CYCLE, DIRECTOR OF FACILITIES PLANNING, AND CHIEF INFORMATION OFFICER IS REVIEWED AND APPROVED BY THE VICE PRESIDENT OF OPERATIONS. THE COMPENSATION COMMITTEE MEETING WAS HELD ON NOVEMBER 18, 2015. TOTAL COMPENSATION FOR THE CEO, CHIEFS AND VICE PRESIDENTS, INCLUDING BONUS PAYMENTS, INCLUDING COMPARABILITY DATA, IS ANALYZED BY INDEPENDENT COMPENSATION CONSULTANTS AND IS DETERMINED TO BE REASONABLE. |
| FORM 990, PART VI, LINE 19 | SUMMARIZED FINANCIAL STATEMENTS ARE AVAILABLE ON THE INFIRMARY'S WEBSITE: WWW.MASSEYEANDEAR.ORG. AUDITED FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. THE INFIRMARY'S GOVERNING DOCUMENTS AND FORM 990 ARE AVAILABLE UPON REQUEST. THE CONFLICT OF INTEREST POLICY IS ALSO AVAILABLE UPON REQUEST. |
| FORM 990, PART XI, LINE 9 | OTHER CHANGES IN NET ASSETS OR FUND BALANCES: ADJUSTMENT FOR PENSION AND POSTRETIREMENT RELATED CHANGES OTHER THAN NET PERIODIC PENSION COST: $3,337,981 |
| Software ID: | |
| Software Version: |